TNTadashi Nagai

Tadashi Nagai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tadashi Nagai has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 November 2009
      • Vol. 50  (11) , 1626-9

    Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome.

    by Hiroshi Okabe, Takahiro Suzuki, Tsukasa Omori, Masaki Mori, Eisuke Uehara, Kaoru Hatano, Masuzu Ueda, Tomohiro Matsuyama, Masaki Toshima, Katsutoshi Qzaki, et al.

    Deferasirox (DFX) is a newly developed oral iron chelator that enables effective chelation with once daily administration. We describe here a case of transfusional-iron overloaded patient who experienced hematopoietic recovery after DFX administration. A 75-year-old woman with iron overload, who had been diagnosed with MDS (RCMD) and had received a transfusion of red blood cells and platelets regularly for 3 years, enrolled in the phase I clinical trial of ICL670 (DFX) in Japan. DFX administration steadily decreased her serum ferritin levels and chelated overloaded iron effectively. Interestingly, a year after initiation of the trial, she needed fewer blood transfusions, and no more transfusions after the 17th month of the trial. Even after suspending transfusions, her hemoglobin level and platelet count increased continuously, and she now has stable disease without blood transfusions. She has not received any specific treatment for MDS during this period. Examination of the bone marrow aspirates in the 35th month revealed dysplastic cells, indicating no remarkable change in the state of MDS. This case suggests that excess iron hampers hematopoiesis and that adequate iron chelation may improve hematological data in some iron-overloaded patients.


  • Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2

    by Tadashi Nagai, Satoru Kikuchi, Ken Ohmine, Takuji Miyoshi, Makiko Nakamura, Takahito Kondo, Kazumichi Furuyama, Norio Komatsu, Keiya Ozawa

    Heme plays an important biomodulating role in various cell functions. In this study, we examined the effects of hemin on cellular sensitivity to imatinib and other anti‐leukemia reagents. Hemin treatment of human BCR/ABL‐positive KCL22 leukemia cells increased IC50 values of imatinib, that is, the drug resistance, in a dose‐dependent manner without any change in the BCR/ABL kinase activity. Imatinib‐induced apoptosis was also suppressed by hemin treatment in KCL22 cells. Hemin treatment increased the activity of γ‐glutamylcysteine synthetase (γ‐GCS) light subunit gene promoter, which contains a Maf recognition element (MARE). Protein levels of γ‐GCS and heme oxygenase‐1 (HO‐1), two MARE‐containing genes, were also increased after hemin treatment. Knockdown of Nrf2 expression by RNA interference largely abolished the effect of hemin on imatinib‐treated cells, suggesting that Nrf2 recognition of MARE is essential for the hemin‐mediated protective effect. Similar to hemin, treatment of cells with δ‐aminolevulinic acid (δ‐ALA), the obligatory heme precursor, also increased IC50 values of imatinib. In contrast, inhibition of cellular heme synthesis by succinylacetone increased the sensitivity of cells to imatinib in two imatinib‐resistant cell lines, KCL22/SR and KU812/SR. Hemin treatment also decreased the sensitivity of cells to four anthracyclins, daunorubicin, idarubicin, doxorubicin, and mitoxantrone, in BCR/ABL‐negative leukemia U937 and THP‐1 cells, as well as in KCL22 cells. These findings thus indicate that cellular heme level plays an important role in determining the sensitivity of cells to imatinib and certain other anti‐leukemia drugs and that the effect of heme may be mediated via its ability to upregulate Nrf2 activity. J. Cell. Biochem. 104: 680–691, 2008.


    • 1 August 2007
      • Vol. 48  (8) , 624-31

    [Benefits of mycophenolate mofetil for refractory graft-versus-host disease].

    by Masaki Mori, Kazuo Muroi, Tomohiro Matsuyama, Satoko Oka, Yoko Ono, Chizuru Yamamoto, Mitsuyo Uesawa, Hiroshi Okabe, Haruko Matsu, Raine Tatara, et al.

    We retrospectively evaluated the efficacy of mycophenolate mofetil (MMF) in the treatment of steroid-resistant acute and chronic graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation. Thirteen patients, ten men and three women, consisted of 5 cases of acute myelogenous leukemia, 2 of acute lymphoblastic leukemia, 2 of chronic myelogenous leukemia, 2 of lymphoblastic lymphoma, and 1 case each of adult T-cell leukemia and peripheral T-cell lymphoma. The transfusions consisted of 5 peripheral blood, 7 bone marrow and 1 cord blood from 3 mothers, 4 siblings and 6 unrelated donors with conditioning treatments, including 8 total-body irradiation-based regimens, and 2 busulfan plus cyclophosphamide and 2 reduced-intensity regimens. GVHD prophylaxis included FK506 plus methotrexate (MTX) and/or antithymocyte globulin for 9 patients, and cyclosporine and MTX for 4 patients. All patients were treated with second-line MMF for steroid-refractory acute and/or chronic GVHD, and 11 patients improved. The adverse events were tolerable except for one patient in whom grade 3 neutropenia forced discontinuation of treatment. No case of non-relapse mortality occurred. We consider that MMF is beneficial and well tolerated for treatment of steroid-refractory GVHD.

  • Severe Hepatitis and Complete Molecular Response Caused by Imatinib Mesylate: Possible Association of Its Serum Concentration with Clinical Outcomes

    by Satoru Kikuchi, Kazuo Muroi, Satoko Takahashi, Chizuru Kawano-Yamamoto, Masaaki Takatoku, Akira Miyazato, Tadashi Nagai, Masaki Mori, Norio Komatsu, Keiya Ozawa

    A 40-year-old female with chronic myelogeneous leukemia (CML) in the chronic phase was treated with imatinib mesylate (STI571) because of interferon resistance. She achieved complete cytogenetic response but not complete molecular response 3 months after STI571 administration. Six months later, she developed severe liver damage without evidence of actively infectious hepatitis A, B, C, G, E, TT virus, Epstein-Barr virus or cytomegalovirus. A significant serum level of STI571 (107 ng/ml) was detected, although she had not taken the drug for 6 days. Liver biopsy demonstrated massive hepatic necrosis, consistent with drug-induced hepatitis. She achieved complete molecular response, although she did not take STI571 for 47 days after the development of hepatitis. These results suggest that both hepatitis and molecular response were associated with the serum STI571 concentration.


    • 1 October 2004
      • Vol. 45  (10) , 1138-40

    [Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient].

    by Yoko Obara, Tadashi Nagai, Masaki Mori, Ken Ohmine, Masaki Toshima, Norio Komatsu, Keiya Ozawa

    A 56-year-old woman with acute myeloid leukemia had two rapidly growing necrotizing nodules with ulcer formation on her head after the first course of consolidation therapy. Clinical features corresponding to sepsis (e.g., fever) appeared following the development of the skin lesion. Pseudomonas aeruginosa was isolated from the blood as well as pus of the lesion. Based on these findings, a diagnosis of ecthyma gangrenosum was made. Treatment with ciprofloxacin and gamma-globulin dramatically improved the patient's clinical features. Since Pseudomonas sepsis with ecthyma gangrenosum is associated with a high mortality rate, it is important to start immediate treatment with appropriate antibiotics.

  • Open Access

    Erythropoietin Overcomes Imatinib‐Induced Apoptosis and Induces Erythroid Differentiation in TF‐1/bcr‐abl Cells

    by Mie Uchida, Tomoko Watanabe, Masae Kunitama, Masaki Mori, Satoru Kikuchi, Kozue Yoshida, Keita Kirito, Tadashi Nagai, Keiya Ozawa, Norio Komatsu

    Targeting BCR‐ABL tyrosine kinase by treatment with the selective inhibitor imatinib (formerly STI571, Gleevec) has proved to be highly efficient for inhibiting leukemic growth in vitro. In addition, in clinical trials, imatinib has produced high response rates in patients with chronic myeloid leukemia (CML) in chronic phase and blastic crisis. However, episodes of severe cytopenia were also frequently observed, leading to discontinuation of therapy in some cases. Therefore, it is important to examine whether administration of cytokines overcomes the adverse effects of imatinib in in vitro systems. In this study, we examine the effects of granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) and erythropoietin (EPO) on TF‐1/bcr‐abl (which was generated by transduction of a bcr‐abl fusion gene into the TF‐1 cell line) as a model system for CML with blastic crisis. Imatinib induced apoptosis in TF‐1/bcr‐abl cells but not in the parental TF‐1 cells. However, GM‐CSF, a survival factor of the parental TF‐1 cells, protected TF‐1/bcr‐abl cells from imatinib‐induced apoptosis in a dose‐dependent manner. Concomitantly, constitutive phosphorylation of Stat5 and FKHRL1 was significantly inhibited by imatinib, and the inhibition was canceled by the addition of GM‐CSF, accompanied by upregulation of Bcl‐xL and downregulation of p27/Kip1. In addition, although untreated TF‐1/bcr‐abl cells had lost responsiveness to both GM‐CSF and EPO and showed autonomous growth, GM‐CSF enhanced phosphorylation of Stat5 and FKHRL1 in these cells. Importantly, imatinib‐treated TF‐1/bcr‐abl cells differentiated into hemoglobin‐positive cells in the presence of EPO, as in the case for the parental TF‐1 cells. Taken together, imatinib‐treated CML cells may differentiate into mature cells in the presence of differentiation‐inducing cytokines such as EPO.


    • 1 September 2003
      • Vol. 44  (9) , 968-70

    [Successful treatment of refractory acute GVHD with mycophenolate mofetil after peripheral blood stem cell transplantation from the patient's one locus-mismatched mother].

    by Takuji Miyoshi, Chizuru Kawano-Yamamoto, Takahiro Nagashima, Tadashi Nagai, Norio Komatsu, Kazuo Muroi, Keiya Ozawa

    A 35-year-old male with chronic myeloid leukemia in the accelerated phase received a peripheral blood stem cell transplant from his HLA-DR-mismatched mother. Graft-versus-host disease (GVHD) prophylaxis was with short-term methotrexate and tacrolimus. After transplantation, grade II skin acute GVHD occurred and was unsuccessfully treated with bolus methylprednisolone administration. The acute GVHD progressed to grade III of the skin, gut and liver, and mycophenolate mofetil (MMF) was accordingly administered at a daily dose of 2 g. This treatment resulted in a dramatic improvement in the clinical features of the acute GVHD. The patient suffered from hemorrhagic cystitis and several episodes of cytomegalovirus antigenemia. MMF may be useful for steroid-resistant acute GVHD despite an increasing risk of viral infections.

  • Open Access

    Analysis of Gene Expression Profiles in an Imatinib‐Resistant Cell Line, KCL22/SR

    by Ken Ohmine, Tadashi Nagai, Takahisa Tarumoto, Takuji Miyoshi, Kazuo Muroi, Hiroyuki Mano, Norio Komatsu, Fumimaro Takaku, Keiya Ozawa

    The BCR/ABL tyrosine kinase inhibitor, imatinib, has shown substantial effects in blast crises of chronic myelogenous leukemia. However, most patients relapse after an initial clinical response, indicating that drug resistance is a major problem for patients being treated with imatinib. In this study, we generated a new imatinib‐resistant BCR/ABL‐positive cell line, KCL22/SR. The 50% inhibitory concentration of imatinib was 11‐fold higher in KCL22/SR than in the imatinib‐sensitive parental cell line, KCL22. However, KCL22/SR showed no mutations in the BCR/ABL gene and no increase in the levels of BCR/ABL protein and P‐glycoprotein. Furthermore, the level of phosphorylated BCR/ABL protein was suppressed by imatinib treatment, suggesting that mechanisms independent of BCR/ABL signaling are involved in the imatinib resistance in KCL22/SR cells. DNA microarray analyses demonstrated that the signal transduction‐related molecules, RAS p21 protein activator and RhoA, which could affect Ras signaling, and a surface tumor antigen, L6, were upregulated, while c‐Myb and activin A receptor were downregulated in KCL22/SR cells. Furthermore, imatinib treatment significantly suppressed the level of phosphorylated p44/42 in KCL22 cells but not in KCL22/SR cells, even when BCR/ABL was inhibited by imatinib. These results suggest that various mechanisms, including disturbance of Ras‐mitogen‐activated protein kinase signaling, are involved in imatinib resistance.


  • Massive Immune Hemolysis After Non-myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation with Minor ABO-incompatibility

    by Kaoru Noborio, Kazuo Muroi, Tohru Izumi, Masaki Toshima, Chizuru Kawano-Yamamoto, Tetsuya Otsuki, Tadashi Nagai, Norio Komatsu, Keiya Ozawa

    A 35-year-old male, blood group B, Rh(D)+ type, received an allogeneic peripheral blood stem cell (PBSC) transplant after a non-myeloablative regimen of fludarabine and cyclophosphamide for resistant γ δ cutaneous T-cell lymphoma (CTCL). The donor was his HLA-identical brother, blood group O, Rh(D)+ type. Graft-versus-host disease (GVHD) prophylaxis was performed with cyclosporine alone. On day +8, massive immune hemolysis occurred, followed by acute renal failure. Hemodialysis was performed eight times until recovery of renal function on day +24. The risk of delayed immune hemolysis after non-myeloablative allogeneic PBSC transplantation with minor ABO-incompatibility must be considered.


    • 1 October 2002
      • Vol. 43  (10) , 954-9

    [Acute promyelocytic leukemia accompanied by retinoic acid syndrome with complications of acute myocardial infarction and cerebral infarction during treatment with all-trans retinoic acid].

    by Takuji Miyoshi, Tetsuya Otsuki, Ken Omine, Keita Kirito, Tadashi Nagai, Tohru Izumi, Norio Komatsu, Seiji Madoiwa, Jun Mimuro, Yoichi Sakata, et al.

    A 71-year-old man visited our hospital complaining of fever and a bleeding tendency. The peripheral blood WBC count was 10,400/microliter with 90% promyelocytes. The bone marrow was hypercellular with 88% promyelocytes. Disseminated intravascular coagulation was recognized. The patient was diagnosed as having acute promyelocytic leukemia and was treated with daily oral administration of all-trans retionic acid (ATRA) (45 mg/m2/day) and cytarabine (160 mg/day, intravenous drip infusion for the initial five days). The ATRA treatment induced leukemic cells to undergo mature myeloid differentiation. On day 24 after the start of treatment, the WBC count rapidly increased and acute myocardial infarction appeared, with consciousness disturbance and bilateral Babinski reflex appearing three hours later. Magnetic resonance imaging showed a fresh lacunar infarction of the right lenticular nucleus, and serum levels of IL-6 and PAI-1 were found to be elevated at the onset of infarction. Since there was a possibility that the retinoic acid syndrome (RAS) might have helped bring about the infarctions, we stopped the ATRA treatment and started administration of methyl-prednisolone (500 mg/body/day for 3 days) and gabexate mesilate. The WBC count decreased immediately and the consciousness disturbance improved. In this case, ATRA treatment might have initiated the RAS and resulted in some endothelial damage, thus causing the infarctions.